Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...